Mirum Pharmaceuticals(MIRM)
Focus: Mirum Pharmaceuticals is a publicly traded specialty pharma company focused on small-molecule therapies for rare liver diseases, particularly cholestatic and metabolic conditions. The company operates at peak commercialization stage with established market presence in rare hepatic indications.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
48+19 this month
Growing — net +19 jobs in 30d
29 jobs added vs 10 removed. Steady team buildout.
Should You Work at Mirum Pharmaceuticals?
AI assessmentMirum represents a growth-stage rare disease specialist with near-term commercial momentum but material single-product concentration risk; best fit for professionals seeking commercial scaling experience with tolerance for biotech-level volatility.
Why Work Here
- Strong revenue growth trajectory ($77M in FY2024 to $186M in FY2025, +142% YoY) signals expanding market opportunity and internal investment capacity for career advancement.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$186M
Key Products
Peak
Foundational product generating 53% of company revenue; drives financial stability but creates concentration risk.
Help build intelligence for Mirum Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.